Dexlansoprazole (INN trade names Kapidex Dexilant) is a proton pump inhibitor that is marketed by Takeda Pharmaceuticals. Chemically it is an enantiomer of lansoprazole. The compound was launched in the US for use in the treatment and maintenance of patients with erosive oesophagitis and non-erosive gastro-oesophageal reflux disease (GERD or GORD). Dexlansoprazole was approved by the U.S. Food and Drug Administration (FDA) on January 30 2009.
This page contains content from the copyrighted Wikipedia article "Dexlansoprazole"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
